Azerbaijan Post-Market Supervision of Medical Devices: Current Maturity and Regulatory Gaps

1. Key takeaways

Re-sorting the suspension and revocation grounds of Parts 11 and 12 of Rules No. 345 by their applicability to devices reveals the current maturity of post-market supervision:

Fully applicable to devices: 11.1.3 (non-compliant packaging and labelling with an unheeded warning), 12.1.4 (inconsistencies in the quality indicators of three batches), 12.1.5 (actual composition differing from the registration documents), 11.1.1 (adverse effects not stated in the instructions for use).

Partially applicable, interpretation pending: 11.1.4 (poor quality, ineffectiveness or unsafety under Article 4.3-1 of the Law on Medicines), 12.1.1 (breach of vigilance obligations), 12.1.2 (negative benefit/risk assessment).

Clearly drafted around medicines: 11.1.2 (lack or insufficiency of therapeutic effectiveness), 12.1.3 (a final opinion of non-compliance with good manufacturing practice, GMP).

This distribution shows that post-market device supervision in Azerbaijan is still in a stage of borrowing the drug skeleton. There are no standalone device vigilance rules, no device-specific recall rules, and no device-specific GMP requirements.

2. Legal basis

• Resolution No. 345 of the Cabinet of Ministers of the Republic of Azerbaijan of 18 July 2024 approving the Rules for the State Registration of Medicines, Pharmaceutical Substances and Medical Devices, Their Entry in the State Register and the Maintenance of the State Register (in force from 19 July 2024; Xalq qəzeti No. 151 of 20 July 2024; Legislative Collection 2024, No. 7, Article 906; repealing Resolution No. 108 of 13 July 2007 with effect from 20 July 2024): Articles 11.1.1 to 11.1.4 (suspension), Article 11.2 (full-chain stop and recall), Articles 12.1.1 to 12.1.5 (revocation), Article 12.2 (delivery within 2 working days), Article 12.3 (publication in the periodical press), Article 10.6 (Register entries).
• Resolution No. 503 of the Cabinet of Ministers of the Republic of Azerbaijan of 25 December 2019 on Pharmacovigilance Rules (the current basis of device vigilance), and Resolution No. 460 of the Cabinet of Ministers of the Republic of Azerbaijan of 27 November 2019 on the Rules for the Withdrawal of Medicines (the current basis of device recalls).
• Law of the Republic of Azerbaijan on Licenses and Permits (No. 176-VQ of 15 March 2016), Articles 18.2.1–18.2.3, 19.9, 25 and 26.1: Articles 25 and 26.1 (other statutory grounds for suspension and revocation); for the citation of Article 4.3-1, see Article 11.1.4 of Resolution No. 345 of the Cabinet of Ministers of the Republic of Azerbaijan of 18 July 2024 approving the Rules for the State Registration of Medicines, Pharmaceutical Substances and Medical Devices, Their Entry in the State Register and the Maintenance of the State Register (in force from 19 July 2024; Xalq qəzeti No. 151 of 20 July 2024; Legislative Collection 2024, No. 7, Article 906).

3. Expert insights

Insight one: the regulatory temperature gap stems from the legislative path. Azerbaijan legislated for medicines first and then used the 2023 amendment to bring devices within the same framework by equivalence (Articles 1.0.1 and 1-1), so the post-market provisions naturally carry drug traces. The therapeutic effectiveness language of Article 11.1.2 and the good manufacturing practice language of Article 12.1.3 both need interpretation before they can be applied to devices. This interpretive dependence is both a risk (uncertain criteria) and an opportunity (room for proactive communication).

Insight two: the three-batch inconsistency ground of Article 12.1.4 is the closest substantive regulatory lever for devices. The provision names devices explicitly, and the threshold is low (three batches). In the current absence of a device-specific market surveillance and sampling regime, this provision in practice carries the main burden of device quality supervision. Companies should operate on the principle of archiving every batch and recording every deviation.

Insight three: Article 11.1.3 is the only fully neutral provision and the one most likely to be enforced. Non-compliant packaging or labelling plus an unheeded warning leads to suspension. This ground involves no medicine-specific concept, is cheap to inspect and is easy to evidence, and is expected to become the most common enforcement entry point in practice.

Insight four: the gaps themselves point to the likely legislative direction. Current gaps include device-specific vigilance rules, device-specific recall procedures, device GMP or equivalent quality system requirements, and a device post-market surveillance and sampling regime. Resolution No. 503 (vigilance) and Resolution No. 460 (withdrawal) are both 2019 Cabinet resolutions, and any future device version or amendment of either will directly reshape the obligation list of certificate holders.

Insight five: companies can prepare to the strictest standard and turn the gaps into an advantage. Where criteria are pending, proactively building an adverse event system, batch quality files, recall plans and packaging compliance inspections by reference to the drug rules allows seamless alignment once rules are clarified, and also secures the position on neutral grounds such as Article 11.1.3.

4. Practical recommendations

1. Operate to the strictest standard: maintain at least one adverse event system, one batch quality file, one recall plan and one packaging compliance inspection programme.
2. Set Article 12.1.4 (three batches) as an internal red line: zero tolerance for quality deviations, recorded and reported immediately.
3. Set Article 11.1.3 (packaging and labelling) as a mandatory quarterly inspection item, and complete remediation with a written reply within the warning period.
4. Monitor whether Resolution No. 503 (vigilance) and Resolution No. 460 (withdrawal) are amended or receive device versions, and include this in the quarterly review.
5. Obtain written AEC confirmation on how Article 11.1.2 (therapeutic effectiveness) and Article 12.1.3 (GMP) apply to devices.
6. Mark in the internal compliance manual which provisions are drug-drafted with device criteria still pending, so they are not mistaken for exemptions.

5. Verification checklist

• □ Adverse event system, batch quality files, recall plan and packaging inspections have been built to the strictest standard.
• □ Article 12.1.4 has been set as an internal red line.
• □ Article 11.1.3 is a mandatory quarterly inspection item.
• □ Amendments and device versions of Resolutions No. 503 and No. 460 are on the quarterly review list.
• □ Written AEC confirmation on the applicability of Articles 11.1.2 and 12.1.3 to devices has been obtained.
• □ The compliance manual marks provisions that are drug-drafted with device criteria pending.

• Article 44 — Device vigilance under the current rules: the spillover of the Pharmacovigilance Rules: https://www.grzanglobal.com/azerbaijan-medical-device-registration/vigilance-current-legal-basis/
• Article 42 — Suspension of State registration: 4 grounds and a full stop on import, sale and use: https://www.grzanglobal.com/azerbaijan-medical-device-registration/suspension-of-state-registration/
• Article 49 — The Azerbaijan compliance calendar for the next 12 months: https://www.grzanglobal.com/azerbaijan-medical-device-registration/azerbaijan-compliance-calendar-next-12-months/

Regulatory information verified as of October 30, 2026.

GRZAN supports manufacturers and authorised representatives preparing registration dossiers and post-market compliance documentation for the Azerbaijan market, from strictest-standard vigilance systems and batch quality files to gap monitoring and written AEC confirmations. For tailored assistance with your Azerbaijan medical device documentation, contact us at info@grzanglobal.com.